A pharmacokinetics study of edoxaban in non-small cell lung cancer patients harboring EGFR mutation combined with venous thromboembolism

A pharmacokinetics study of edoxaban in non-small cell lung cancer patients harboring EGFR mutation combined with venous thromboembolism - A pharmacokinetics study of edoxaban in non-small cell lung cancer patients harboring EGFR mutation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021160

Enrollment

Registered

2016-03-01

Start date

2016-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

blood sampling

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pathologically or cytologically diagnosed non-small-cell lung cancer harboring EGFR mutation ECOG PS 0-2 Age over 20 years old. Non-small-cell lung cancer of stage IIIB or IV Reccurence of operation or concurrent chemoradiotherapy 2 months or longer expected survival. Written informed consent.

Exclusion criteria

Exclusion criteria: History of allergic reaction for edoxavan Severe renal dysfunction (Ccr under 30 mL/min) Severe liver disease Interstitial pneumonia Plannning for concurrent chemoradiotherapy Started medication or treatment for VTE Active bleeding Severe hypertention A pregnant woman, a woman in breast-feeding Taking aspirin or two kind os antiplatelet drug Acute infectious endocarditis An inappropriate case judged by doctor in charge

Design outcomes

Primary

Measure	Time frame
Pharmacokinetic analysis	—

Countries

Japan

Contacts

Public ContactYukari Tsubata

Shimane University Faculty of Medicine Department of Internal Medicine Division of Medical Oncology & Respiratory Medicine

ytsubata@med.shimane-u.ac.jp0853-20-2580

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026